Weight Loss 23 January 2026

Novo Nordisk’s CagriSema tops Wegovy in new diabetes trial — 14.2% weight loss at top dose

On Monday, Novo Nordisk announced that its experimental CagriSema injection outperformed its blockbuster Wegovy in a late-stage trial involving adults with type 2 diabetes. At the top dose, patients lost 14.2% of their body weight after 68 weeks, compared to 10.2% with Wegovy. Blood sugar control also improved more with CagriSema, with HbA1c dropping 1.91 percentage points versus 1.76, the company reported. The outcome is critical now as Novo seeks a viable follow-up to Wegovy, with real consequences on the line. Eli Lilly and Co have entered the fray with Zepbound, while CagriSema’s prior data had already rattled investor confidence.

February 2, 2026

Wegovy Pill Is Taking Off: Novo Logs 18,410 U.S. Prescriptions in First Full Week

Analysts reported on Friday that Novo Nordisk’s new weight-loss drug Wegovy was prescribed 18,410 times across the U.S. during its first full week on the market, according to IQVIA prescription data. These initial figures are crucial—they offer investors the first concrete indication of whether patients will opt for a daily pill in a space dominated by weekly injections. Novo aims to leverage its first-mover advantage to secure lasting market share, even as Eli Lilly nears its own oral alternative.

January 23, 2026